Meeting News
Advertisement
The data herein supports the novel role of mutant CCR4 in enhancing T-cell lymphomagenesis and T-helper differentiation.
These highly encouraging data support further evaluation of epcoritamab.
Acalabrutinib and zanubrutinib demonstrated better safety and efficacy outcomes when compared with ibrutinib in CLL/SLL.
Dr. Oluwole discussed new data on brexu-cel in patients with relapsed or refractory ALL.
Dr. Rodríguez-Otero shares the MRD analysis from the phase III PERSEUS trial at the 2024 ASCO Annual Meeting.
Catherine Coombs, MD, outlined some of her research into the solid tumor microenvironment, particularly in prostate cancer.
Advertisement
Dr Cliff describes an analysis of oncology drugs that were approved via the FDA Accelerated Approval Program over 10 years.
Parsaclisib plus ruxolitinib can improve symptoms and spleen volume in certain patients with myelofibrosis.
Acalabrutinib with or without obinutuzumab had sustained safety and efficacy in patients with CLL in six years of follow-up.
Paula Rodríguez Otero, MD, described an updated analysis of the KarMMa-3 trial presented at the 65th ASH Annual Meeting.
Leyla Shune, MD, discusses the import of promising data for ide-cel in multiple myeloma presented at the 2023 ASH Meeting.
Dr. Fonseca, of the Mayo Clinic, spoke with Blood Cancers Today about idecabtagene vicleucel in myeloma treatment.
Elranatamab yielded deep and durable responses in relapsed or refractory multiple myeloma, even with biweekly dosing.
Dara-CVRd was effective as induction therapy prior to and consolidation therapy following AHSCT in ultra-high-risk myeloma.
Motixafortide plus G-CSF mobilized significantly more CD34+ hematopoietic stem and progenitor cells versus placebo in MM.
DDX3X dysregulation is involved in the progression of CLL by facilitating NOTCH1 mRNA translation
Researchers said there was a need for potentially more effective one-time-only treatment options.
Dr. Hans Lee met with Blood Cancers Today to discuss outcomes and treatments after triple-class exposure in multiple myeloma.
It included 21 patients with lymphoma with a median age of 57 who had received a median of four prior lines of therapy.
Dr. Raje shared findings on CAR T-cell therapy in earlier lines of treatment for relapsed or refractory multiple myeloma.
Advertisement
Advertisement
Editorial Board
Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine
Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center
Elias Jabbour, MDExecutive Editor | DB Lane Cancer Research Fund Distinguished Professor in Leukemia Research, MD Anderson Cancer Center
Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University
Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center
Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch
Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.